Should I buy or sell Arrowhead Pharmaceuticals stock right now?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arrowhead Pharmaceuticals in the last year. There are currently 4 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" ARWR shares. View ARWR analyst ratings or view top-rated stocks .

What is Arrowhead Pharmaceuticals' stock price target for 2024?

12 Wall Street research analysts have issued 1-year price targets for Arrowhead Pharmaceuticals' shares. Their ARWR share price targets range from $34.00 to $90.00. On average, they expect the company's stock price to reach $53.45 in the next twelve months. This suggests a possible upside of 122.6% from the stock's current price. View analysts price targets for ARWR or view top-rated stocks among Wall Street analysts .

How have ARWR shares performed in 2024?

Arrowhead Pharmaceuticals' stock was trading at $30.60 on January 1st, 2024. Since then, ARWR stock has decreased by 21.5% and is now trading at $24.01. View the best growth stocks for 2024 here .

When is Arrowhead Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 7th 2024. View our ARWR earnings forecast .

How were Arrowhead Pharmaceuticals' earnings last quarter?

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) announced its quarterly earnings results on Tuesday, February, 6th. The biotechnology company reported ($1.24) EPS for the quarter, missing analysts' consensus estimates of ($0.78) by $0.46. The biotechnology company had revenue of $3.55 million for the quarter, compared to analyst estimates of $35.60 million. Arrowhead Pharmaceuticals had a negative trailing twelve-month return on equity of 90.77% and a negative net margin of 163.32%. The business's revenue was down 94.3% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.39) earnings per share.

What ETFs hold Arrowhead Pharmaceuticals' stock?

ETFs with the largest weight of Arrowhead Pharmaceuticals (NASDAQ:ARWR) stock in their portfolio include Global X Genomics & Biotechnology ETF (GNOM) , Morningstar US Small Growth (MSGR) , Principal Healthcare Innovators ETF (BTEC) , FMC Excelsior Focus Equity ETF (FMCX) , Syntax Stratified MidCap ETF (SMDY) and iShares Biotechnology ETF (IBB) . Invesco Nasdaq Biotechnology ETF (IBBQ) .

What other stocks do shareholders of Arrowhead Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Arrowhead Pharmaceuticals investors own include Bellicum Pharmaceuticals (BLCM) , NVIDIA (NVDA) , AbbVie (ABBV) , Micron Technology (MU) , Alibaba Group (BABA) , Alliance Resource Partners (ARLP) , Bank of America (BAC) , Tesla (TSLA) , Salesforce (CRM) and Advanced Micro Devices (AMD) .

Who are Arrowhead Pharmaceuticals' major shareholders?

Arrowhead Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include Global Assets Advisory LLC (0.03%). Insiders that own company stock include Adeoye Y Olukotun , Backer Marianne De , Christopher Richard Anzalone , Douglas B Given, Douglas B Given , Hongbo Lu, James C Hamilton , James Hassard , Kenneth Allen Myszkowski , Martin Javier San , Patrick O'brien , Tracie Oliver , Victoria Vakiener and William D Waddill . View institutional ownership trends .

How do I buy shares of Arrowhead Pharmaceuticals?

Shares of ARWR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:ARWR

Arrowhead Pharmaceuticals (ARWR) Stock Price, News & Analysis

→ “Forget Tesla, this is Elon’s Next Big Thing” (From InvestorPlace) (Ad)

Free ARWR Stock Alerts

$23.96

-0.05 (-0.21%)

(As of 09:52 AM ET)

Compare

Today's Range: $23.65
▼
$23.96
50-Day Range: $24.01
▼
$36.08
52-Week Range: $20.67
▼
$42.48

Volume: 26,395 shs
Average Volume: 1.49 million shs
Market Capitalization: $2.97 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $53.45

Get Arrowhead Pharmaceuticals alerts:

Arrowhead Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.67 Rating Score
Upside/Downside: 122.6% Upside
$53.45 Price Target
Short Interest: Bearish
7.16% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -2.55
Upright™ Environmental Score
News Sentiment: 1.11
Based on 5 Articles This Week
Insider Trading: Selling Shares
$3.27 M Sold Last Quarter
Proj. Earnings Growth: Growing
From ($2.70) to ($2.53) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.10 out of 5 stars

Medical Sector

171st out of 928 stocks

Pharmaceutical Preparations Industry

65th out of 433 stocks

3.3

Analyst's Opinion

Consensus Rating
Arrowhead Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 8 buy ratings, 4 hold ratings, and no sell ratings.
Amount of Analyst Coverage
Arrowhead Pharmaceuticals has only been the subject of 4 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
7.16% of the outstanding shares of Arrowhead Pharmaceuticals have been sold short.
Short Interest Ratio / Days to Cover
Arrowhead Pharmaceuticals has a short interest ratio ("days to cover") of 6.2.
Change versus previous month
Short interest in Arrowhead Pharmaceuticals has recently decreased by 3.59%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Arrowhead Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Arrowhead Pharmaceuticals does not have a long track record of dividend growth.

3.4

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Arrowhead Pharmaceuticals has received a 39.47% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Cardiovascular siRNA medication", "RNA interference medication for cancer", and "Liver-disease medication (A05)" products. See details.
Environmental Sustainability
The Environmental Impact score for Arrowhead Pharmaceuticals is -2.55.

3.4

News and Social Media Coverage

News Sentiment
Arrowhead Pharmaceuticals has a news sentiment score of 1.11. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.66 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 5 news articles for Arrowhead Pharmaceuticals this week, compared to 4 articles on an average week.
Search Interest
Only 4 people have searched for ARWR on MarketBeat in the last 30 days. This is a decrease of -83% compared to the previous 30 days.
MarketBeat Follows
8 people have added Arrowhead Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 14% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Arrowhead Pharmaceuticals insiders have sold 5,842.34% more of their company's stock than they have bought. Specifically, they have bought $54,990.00 in company stock and sold $3,267,693.00 in company stock.
Percentage Held by Insiders
Only 4.50% of the stock of Arrowhead Pharmaceuticals is held by insiders.
Percentage Held by Institutions
62.61% of the stock of Arrowhead Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Arrowhead Pharmaceuticals are expected to grow in the coming year, from ($2.70) to ($2.53) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Arrowhead Pharmaceuticals is -8.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Arrowhead Pharmaceuticals is -8.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Arrowhead Pharmaceuticals has a P/B Ratio of 8.96. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad InvestorPlace

Forget Nvidia, buy this A.I. Stock Now

Forget Nvidia, Microsoft or Google. Our tech expert and venture capitalist Luke Lango believes this is Elon Musk’s favorite A.I. stock. Why? Because this company is supplying Elon Musk with a key piece of advanced tech for his new A.I. venture.

Click here to see the details.

About Arrowhead Pharmaceuticals Stock (NASDAQ:ARWR)

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.

ARWR Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ARWR Stock News Headlines

March 21, 2024 | insidertrades.com

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Director Acquires $27,490.00 in Stock

April 11, 2024 | americanbankingnews.com

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Given Average Rating of "Moderate Buy" by Brokerages

April 16, 2024 | InvestorPlace (Ad)

Forget Nvidia, buy this A.I. Stock Now

April 10, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Arrowhead Pharmaceuticals Following Promising Plozasiran Trial Results

April 7, 2024 | businesswire.com

Arrowhead Pharmaceuticals Announces New Phase 2 Data of Plozasiran Published in JAMA Cardiology and Presented at American College of Cardiology 73rd Annual Scientific Session & Expo

April 5, 2024 | investorplace.com

The 7 Most Undervalued Russell 2000 Stocks to Buy in April 2024

March 30, 2024 | seekingalpha.com

Arrowhead: RNAi Specialist Struggling To Show A Strong Hand (Rating Downgrade)

March 25, 2024 | finance.yahoo.com

Arrowhead Pharmaceuticals Initiates Expanded Access Program for Plozasiran and Announces Upcoming Presentation of Clinical Data

April 16, 2024 | InvestorPlace (Ad)

Forget Nvidia, buy this A.I. Stock Now

March 16, 2024 | finance.yahoo.com

ARWR Apr 2024 20.000 put

March 16, 2024 | nasdaq.com

Noteworthy Thursday Option Activity: ARWR, RBLX, MRNA

March 16, 2024 | finance.yahoo.com

ARWR Apr 2024 25.000 call

March 15, 2024 | stocknews.com

Biotech Investors: Should You Buy, Hold, or Sell Moderna (MRNA) and Arrowhead Pharmaceuticals (ARWR)?

March 14, 2024 | markets.businessinsider.com

Analysts’ Top Healthcare Picks: Edwards Lifesciences (EW), Arrowhead Pharmaceuticals (ARWR)

March 13, 2024 | investorplace.com

7 Biotech Stocks to Buy as Sector Rotation Ramps Up

March 12, 2024 | morningstar.com

Arrowhead Pharmaceuticals Inc ARWR

March 11, 2024 | investorplace.com

The 3 Most Undervalued Russell 2000 Stocks to Buy in March 2024

March 9, 2024 | finance.yahoo.com

Arrowhead Pharmaceuticals Inc CFO Kenneth Myszkowski Sells 40,000 Shares

March 8, 2024 | markets.businessinsider.com

Arrowhead Pharmaceutical Gains Over Initiation Of Phase 1/2a Study Of ARO-DM1

March 8, 2024 | businesswire.com

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DM1 for Treatment of Type 1 Myotonic Dystrophy

February 28, 2024 | msn.com

Arrowhead Pharmaceuticals jumps amid takeover speculation

February 25, 2024 | investorplace.com

7 Oversold Russell 2000 Stocks to Add to Your February Buy List

February 17, 2024 | ca.finance.yahoo.com

ARWR Mar 2024 30.000 call

February 12, 2024 | nasdaq.com

Arrowhead Pharmaceuticals, Inc. Common Stock (ARWR)

February 8, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Arrowhead Pharmaceuticals with Strong Growth Projections and Pipeline Potential

February 8, 2024 | markets.businessinsider.com

Strategic Developments and Financial Strength Underpin Buy Rating for Arrowhead Pharmaceuticals

February 8, 2024 | finance.yahoo.com

ARWR: Pipeline Reprioritization to Reduce Cash Burn by up to $100 Million This Fiscal Year

See More Headlines

Receive ARWR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arrowhead Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/06/2024
Today: 4/16/2024
Next Earnings (Estimated): 5/07/2024
Fiscal Year End: 9/30/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:ARWR
CUSIP: N/A
CIK: 879407
Web: www.arrowheadpharma.com
Phone: (626) 304-3400
Fax: 626-304-3401
Employees: 525
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $53.45
High Stock Price Target: $90.00
Low Stock Price Target: $34.00
Potential Upside/Downside: +122.6%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.67
Research Coverage: 12 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.78)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-205,270,000.00
Net Margins: -163.32%
Pretax Margin: -166.93%
Return on Equity: -90.77%
Return on Assets: -38.56%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 3.73
Quick Ratio: 3.73

Sales & Book Value

Annual Sales: $240.74 million
Price / Sales: 12.36
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.68 per share
Price / Book: 8.96

Miscellaneous

Outstanding Shares: 123,900,000
Free Float: 118,322,000
Market Cap: $2.97 billion
Optionable: Optionable
Beta: 0.71

Beginner's Guide to Pot Stock Investing

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

Dr. Christopher R. Anzalone Ph.D. (Age 55)
CEO, President & Director
Comp: $1.6M
Mr. Kenneth A. Myszkowski (Age 58)
Chief Financial Officer
Comp: $834.34k
Mr. Patrick O'Brien J.D. (Age 60)
PharmD, COO, General Counsel & Secretary
Comp: $835.14k
Dr. James C. Hamilton M.D. (Age 46)
MBA, Chief of Discovery & Translational Medicine
Comp: $762.14k
Dr. Mark M. Davis Ph.D.
Founder and Founder & Director of Insert Therapeutics Inc & Calando
Dr. Vincent Anzalone CFA
Head of Investor Relations & VP
Mr. Howard Lovy
Director of Communications
Dr. Bruce D. Given M.D. (Age 70)
Chief Medical Scientist
Comp: $486.31k
Dr. Mark Seefeld (Age 70)
Head of Toxicology & VP
Ms. Tracie Oliver (Age 62)
Chief Commercial Officer
Comp: $449.58k

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ARWR Stock Analysis - Frequently Asked Questions

Should I buy or sell Arrowhead Pharmaceuticals stock right now?: 12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arrowhead Pharmaceuticals in the last year. There are currently 4 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" ARWR shares.
View ARWR analyst ratings or view top-rated stocks.
What is Arrowhead Pharmaceuticals' stock price target for 2024?: 12 Wall Street research analysts have issued 1-year price targets for Arrowhead Pharmaceuticals' shares. Their ARWR share price targets range from $34.00 to $90.00. On average, they expect the company's stock price to reach $53.45 in the next twelve months. This suggests a possible upside of 122.6% from the stock's current price.
View analysts price targets for ARWR or view top-rated stocks among Wall Street analysts.
How have ARWR shares performed in 2024?: Arrowhead Pharmaceuticals' stock was trading at $30.60 on January 1st, 2024. Since then, ARWR stock has decreased by 21.5% and is now trading at $24.01.
View the best growth stocks for 2024 here.
When is Arrowhead Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 7th 2024.
View our ARWR earnings forecast.
How were Arrowhead Pharmaceuticals' earnings last quarter?: Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) announced its quarterly earnings results on Tuesday, February, 6th. The biotechnology company reported ($1.24) EPS for the quarter, missing analysts' consensus estimates of ($0.78) by $0.46. The biotechnology company had revenue of $3.55 million for the quarter, compared to analyst estimates of $35.60 million. Arrowhead Pharmaceuticals had a negative trailing twelve-month return on equity of 90.77% and a negative net margin of 163.32%. The business's revenue was down 94.3% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.39) earnings per share.

What ETFs hold Arrowhead Pharmaceuticals' stock?: ETFs with the largest weight of Arrowhead Pharmaceuticals (NASDAQ:ARWR) stock in their portfolio include Global X Genomics & Biotechnology ETF (GNOM), Morningstar US Small Growth (MSGR), Principal Healthcare Innovators ETF (BTEC), FMC Excelsior Focus Equity ETF (FMCX), Syntax Stratified MidCap ETF (SMDY) and iShares Biotechnology ETF (IBB).Invesco Nasdaq Biotechnology ETF (IBBQ).
What other stocks do shareholders of Arrowhead Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Arrowhead Pharmaceuticals investors own include Bellicum Pharmaceuticals (BLCM), NVIDIA (NVDA), AbbVie (ABBV), Micron Technology (MU), Alibaba Group (BABA), Alliance Resource Partners (ARLP), Bank of America (BAC), Tesla (TSLA), Salesforce (CRM) and Advanced Micro Devices (AMD).
Who are Arrowhead Pharmaceuticals' major shareholders?: Arrowhead Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include Global Assets Advisory LLC (0.03%). Insiders that own company stock include Adeoye Y Olukotun, Backer Marianne De, Christopher Richard Anzalone, Douglas B Given, Douglas B Given, Hongbo Lu, James C Hamilton, James Hassard, Kenneth Allen Myszkowski, Martin Javier San, Patrick O'brien, Tracie Oliver, Victoria Vakiener and William D Waddill.
View institutional ownership trends.
How do I buy shares of Arrowhead Pharmaceuticals?: Shares of ARWR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ARWR) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Arrowhead Pharmaceuticals (ARWR) Stock Price, News & Analysis

Arrowhead Pharmaceuticals MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Arrowhead Pharmaceuticals Stock (NASDAQ:ARWR)

ARWR Stock Price History

ARWR Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

ARWR Stock Analysis - Frequently Asked Questions

Overall MarketRank^™